{4-[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL | 521064-76-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {4-[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL
• 英文别名: {4-[4-Chloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-phenyl}-methanol；[4-[[4-chloro-6-(5-chloro-2-methylphenyl)-1,3,5-triazin-2-yl]amino]phenyl]methanol
• CAS: 521064-76-6
• 化学式: C₁₇H₁₄Cl₂N₄O
• 分子量: 361.23
• InChiKey: GXNTWOSPUZMLQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  70.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {4-[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL 在 (diethylamino)sulfur trifluoride 作用下， 以 二氯甲烷 、 水 为溶剂， 以14%的产率得到6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-FLUOROMETHYL-PHENYL)-[1,3,5]-TRIAZINE-2,4-DIAMINE
  参考文献：
  名称：

  Aryl triazines as LPAAT-SS inhibitors and uses thereof

  摘要：

  本发明涉及芳基三嗪及其用途，包括用于抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或诸如肿瘤细胞的细胞增殖。

  公开号：

  US20030153570A1
• 作为产物：
  描述：

  2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine 、 对氨基苯甲醇 以provided the title compound (50 mg, 62% yield)的产率得到{4-[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL
  参考文献：
  名称：

  Aryl triazines as LPAAT-β inhibitors and uses thereof

  摘要：

  该发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰转移酶β（LPAAT-β）活性和/或细胞增殖，如肿瘤细胞的用途。

  公开号：

  US07618968B2

文献信息

• [EN] 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DERIVES DE 6-PHENYL-N-PHENYL-(1,3,5)-TRIAZINE-2,4-DIAMINE ET COMPOSES APPARENTES AYANT UN EFFET INHIBITEUR DE L'ACIDE LYSOPHOSPHATIDIQUE ACYLTRANSFERASE BETA (LPAAT-BETA) ET DESTINES A ETRE UTILISES POUR TRAITER LE CANCER
  申请人：CELL THERAPEUTICS INC

  公开号：WO2003037346A1

  公开（公告）日：2003-05-08

  The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells, where R1-R5 are hydrogen or non-ydrogen substituents, and Q is a heteroatom or heteroatom attached to one or more methylene groups.

  该发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰转移酶β（LPAAT-β）活性和/或细胞增殖，如肿瘤细胞，其中R1-R5是氢或非氢取代基，Q是杂原子或附加在一个或多个亚甲基基团上的杂原子。
• Aryl triazines as LPAAT-beta inhibitors and uses thereof
  申请人：Bhatt Rama

  公开号：US20080064700A1

  公开（公告）日：2008-03-13

  The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.

  本发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰转移酶β（LPAAT-β）活性和/或细胞增殖，例如肿瘤细胞。
• TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS
  申请人：The Trustees of Princeton University

  公开号：US20160346309A1

  公开（公告）日：2016-12-01

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
• US7291616B2
  申请人：——

  公开号：US7291616B2

  公开（公告）日：2007-11-06
• US7618968B2
  申请人：——

  公开号：US7618968B2

  公开（公告）日：2009-11-17